NFL Hall-of-Famer OJ Simpson Dies of Prostate Cancer

News
Article

The former NFL player, O.J. Simpson, died of cancer at the age of 76, according to a family statement.

Photo Credits: Steve Marcus/UPI/Shutterstock.com

O.J. Simpson died at age 76 from cancer.

Photo Credits: Steve Marcus/UPI/Shutterstock

O.J. Simpson, football hall-of-famer who was acquitted for murder in 1994, died of cancer, according to a statement from his family.

"On April 10th, our father, Orenthal James Simpson, succumbed to his battle with cancer. He was surrounded by his children and grandchildren. During this time of transition, his family asks that you please respect their wishes for privacy and grace," a statement from his family said.

He was reportedly diagnosed with prostate cancer.

Simpson, who was inducted into the Pro Football Hall of Fame in 1985 after playing for the Buffalo Bills and San Francisco 49ers, was 76 at the time of his death.

He was a running back at the University of Southern California, where he won the Heisman Trophy during his senior year in 1968. In 1969, Simpson was drafted as the first overall draft pick for the Buffalo Bills, where he went All-Pro in 1972 and became the first player to rush for 2,000 yards in 1973.

Two decades later, however, Simpson was accused of murdering his ex-wife, Nicole Brown Simpson. He was found not guilty in October 1995, two years before he was sued in civil court and found liable for the murders. Then, in 2008, he was found guilty of robbery and kidnapping after a 2007 incident where he stole sports memorabilia he believed was stolen from him. He spent nine years in prison.

The football player mentioned a cancer diagnosis in a May 2023 video on X (formerly known as Twitter). Then, in 2024, he posted another video denying allegations that he was in hospice care.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL